Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Brands earnings

This article was originally published in The Tan Sheet

Executive Summary

The weak cough/cold season and industry's voluntary removal of some pediatric cough/cold products contributed to a 1 percent drop in Prestige Brands Holdings' third-quarter revenues to $45.1 million compared to the prior-year period, the consumer products firm says Feb. 8. Prestige Brands also notes "competitive pressures on the Doctor's NightGuard dental protector" contributed to the decline. However, strong sales of the Murine brand and Clear Eyes helped soften the cough/cold revenue losses. Despite these problems, the company's overall third-quarter revenue is slightly ahead of the previous year's by $100,000 for a total of $80.2 million in the quarter...

You may also be interested in...



QUOTED. 18 June 2021. Harith Rajagopalan.

Fractyl Health closed a $100m financing round to support ongoing development of duodenal mucosal resurfacing (DMR) technology that addresses root causes of type 2 diabetes. CEO Harith Rajagopalan spoke of his hopes for the technology.

Will COVID Finally Help US FDA And Sponsors Overcome Their ‘Angst’ On Innovative Trial Designs?

The ‘sea change’ inside White Oak should be seen as very encouraging for sponsors, FDA official says.

Domestic In-Person Inspection Work Could Be Back To Normal This Summer, Woodcock Says

Foreign facility visits may take longer to reach usual levels because of the ongoing coronavirus outbreaks in other countries.

Topics

UsernamePublicRestriction

Register

PS101352

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel